Session date: 
01/28/2020 - 11:00am to 11:45am

Pharmacy Grand Rounds

A Second and Third Look at TKI Management in CML

  • ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
  • Session Type: Knowledge-based
  • CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
    • AAPA Category 1 CME Credits
    • ACPE
    • AMA PRA Category 1 Credits™
    • ANCC
  • Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)
MN-RO-AL-MN-459-MAYO LH

Interactive Video Conference Room(s): 
MN-RO-GO-19-101 BARRETTE LH

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

The FDA approval of imatinib in 2001 revolutionized the treatment of chronic myeloid leukemia (CML) by significantly improving life expectancy in this patient population.  Following the approval of imatinib, second generation tyrosine kinase inhibitors (TKIs) dasatinib, nilotinib, and bosutinib and third generation TKI ponatinib, also found their place in CML treatment. This presentation will review the safety and efficacy profiles of each of these drugs along with unique aspects of their management.  Understanding the potential negative effects on quality of life due to adverse effects, pill burden, and financial toxicities in a patient taking a TKI for long-term management of CML, current National Comprehensive Cancer Network (NCCN) guidelines emphasize the safety of TKI discontinuation in certain patients. This presentation will also review the data regarding discontinuation of TKIs, assist in identifying appropriate patients for TKI discontinuation, and discuss TKI withdrawal syndrome.

At the conclusion of this knowledge-based CE session, participants should be able to:

  1. Compare the safety and efficacy profiles of the tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia.
  2. Review the data supporting tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia.
  3. Develop an understanding of which patients are appropriate to consider for tyrosine kinase inhibitor discontinuation and the monitoring that is required following discontinuation.

PDF icon Session Announcement

PDF icon Session Slides

FACULTY INFORMATION

Jade L. Kutzke, PharmD, BCPSPicture of Jade L. Kutzke, PharmD
PGY2 Oncology Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Dr. Kutzke earned a PharmD degree from South Dakota State University in Brookings, SD and completed PGY1 residency training at Mayo Clinic Hospital-Rochester. She is a current PGY2 Oncology Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests include hematology, oncology, and bone marrow transplant.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

  • Jade L. Kutzke, PharmD, BCPS
    • Declares no financial relationships pertinent to this session
    • Declares off-label use of devices and medications will not be discussed during this presentation

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

  • Brenda Amaris
  • Mary Ellen Cordes, MS, APRN, CNC, NE-BC
  • Michael Huckabee, MPAS, PA-C, PhD
  • Wayne (Nick) Nicholson, MD, PharmD, BCPS
  • Garrett Schramm, PharmD, BCPS
  • Lee Skrupky, PharmD, BCPS
Presenter: 
Jade L. Kutzke, PharmD, BCPS
Where did the idea for the course originate?: 
Minnesota
Please login or register to take this course.
Where did the idea for the course originate?: 
Minnesota